Objective: This study aimed to evaluate the safety and efficacy of lobaplatin in hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastasis (PM) arising from colorectal or appendiceal cancer.
Materials and methods: Patients with synchronous or metachronous PM who underwent cytoreductive surgery (CRS) with HIPEC were systematically reviewed at the China National Cancer Center and Huanxing Cancer Hospital from June 2017 to June 2019. All enrolled patients were grouped into either lobaplatin or nonlobaplatin groups depending on the different chemotherapeutic agents used during HIPEC. Clinical characteristics, pathological features, perioperative parameters, and prognostic data were collected and analyzed.
Results: A total of 100 patients were enrolled, with 48 patients in the lobaplatin group and 52 in the nonlobaplatin group. The two groups were well balanced in terms of clinicopathological characteristics. The two groups had comparable perioperative outcomes. However, more patients in the lobaplatin group than in the nonlobaplatin group developed abnormal platelet levels on postoperative day (POD)3 and abnormal ALT levels on POD5. Moreover, the average platelet count in the lobaplatin group was significantly lower than that in the nonlobaplatin group on POD5. There were no significant differences in the 3-year overall survival (OS) rates (48.4% vs 35.1%, P=0.298) and the 3-year progression-free survival (PFS) rates (34.9% vs 21.0%, P=0.470) of the two groups.
Conclusion: Lobaplatin-based HIPEC is safe and feasible for the treatment of patients with PM arising from colorectal or appendiceal cancer with comparable low mortality and acceptable morbidity.
Keywords: HIPEC; lobaplatin; morbidity; peritoneal metastasis; safety; survival.
© 2020 Pei et al.